Global drug sales to grow 5%-8% through 2014 despite patent losses, says IMS

Share this article:
Plavix ceded 90% of its market share to generics within two months
Plavix ceded 90% of its market share to generics within two months
Global sales of pharmaceuticals will grow at a rate of 5%-8% annually over the next five years, IMS Health forecasts – even as products with sales of more than $142 billion lose patent protection in top markets, reducing drug spending by $80-$100 billion.

“This forecast period covers the years in which we have a significant number of major products losing patent protection in developed markets,” said IMS SVP healthcare insights Murray Aitken. “Nevertheless, we are forecasting this relatively strong growth on the basis of continued high levels of patient demand for pharmaceuticals and a strong level of growth from the emerging markets, particularly those we refer to as the pharmerging markets.”

IMS forecasts 14%-17% growth in its “pharmerging markets” for the five-year period, with those markets contributing between $120 billion and $140 billion in growth. Major developed markets will grow 3%-6%, IMS predicted, contributing about the same amount in dollars as the fast-growing markets in poorer countries.

The US will remain the top market, with 3%-6% growth through 2014 and sales reaching $360-$390 billion, despite staggering patent losses. The US represents about two-thirds of the value of the impending patent losses, said Aitken, and six of the world's ten best-selling drugs are set to face generic competition in the next two years: Lipitor, Plavix, Advair, Seroquel, Singulair and Actos.

For 2010, IMS has predicted global pharmaceutical sales growth of 4%-6%. Last year, the market grew 7% to $837 billion.
 
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...